Tendyne Holdings, Inc., a Roseville, MN-based clinical stage medical device company developing technologies for transcatheter mitral valve replacement, secured $25m in Series C financing.
The round was led by Apple Tree Partners, with participation from Boulle Group members and other existing investors. In conjunction with the funding, David McIntyre, a Partner at Apple Tree Partners, will join the Board of Directors at Tendyne.
The company intends to use the funds for validation of its novel Transcatheter Mitral Valve Implant to treat mitral regurgitation, including forthcoming clinical trials.
Led by Jeff Franco, Founder and CEO, Tendyne provides a transcatheter mitral valve replacement prosthesis for the treatment of both functional and degenerative mitral regurgitation. Its mitral valve is deployed and secured while preserving the sub-valvular apparatus. The valve will initially be implanted transapically in a simple procedure that allows the physician to re-position or retrieve the valve after full deployment.
FinSMEs
09/04/2014